Small cell lung cancer (SCLC) is a rapidly progressing, incurable cancer that frequently spreads to bone. New insights are needed to identify therapeutic targets to prevent or retard SCLC metastatic progression. Human SCLC SBC-5 cells in mouse xenograft models home to skeletal and non-skeletal sites while human SCLC SBC-3 cells only pervade non-skeletal sites. 
Introduction
Small cell lung cancer (SCLC), a highly aggressive form of lung cancer associated with tobacco smoking (1-2), represents 10-15% of all lung cancers (3) (4) . Treatment is challenging because SCLC grows rapidly, often becoming well established in lung before becoming symptomatic; metastatic spread occurs early and rapidly (5) (6) . For patients with localized or regionalized SCLC, 5-year survival in the US in 2008 was 52% and 25% respectively (7). For those who suffer metastatic SCLC or relapse, the prognosis is worse. Although there have been advances in therapy for localized SCLC with the introduction of positron emission tomography (PET), SCLC mortality has remained unchanged over the past 30 years (6).
Compared to our knowledge of skeletal metastases in breast and prostate cancers, we know very little about cell and molecular mechanisms of skeletal metastases in lung cancer, especially in SCLC. In osteolytic lesions, such as those in breast cancer, bone loss predominates, while increased bone turnover in which both bone formation and bone resorption are deregulated, is characteristic of skeletal metastases in prostate cancer (8) (9) .
Over one third of patients with SCLC develop osteolytic bone metastasis, resulting in severe pain, pathologic fractures, spinal cord compression and loss of mobility to greatly reduce quality of life (10-11). Because of the lack of therapeutic options in SCLC, there is an urgent need to better understand how skeletal progression in SCLC may be controlled and treated.
MicroRNAs (miRNAs) critically regulate tumorigenesis and progression by targeting 6 morphology (27) . Osteolytic bone lesions were observed throughout the skeleton of mice with SBC-5 cell xenografts, while no bone lesions were observed in mice with SBC-3 cell xenografts (27) . We applied this model to study skeletal progression of SCLC in the preclinical studies reported here.
Our goal was to investigate miRNAs involved in the regulation of skeletal metastatic SCLC lesions. A comparison of miRNA profiles of SBC-5 and SBC-3 cell lines revealed selective down-regulation in miR-335 and miR-29a in SBC-5 cells. Over-expression of miR-335, but not miR-29a, in SBC-5 cells decreased cell proliferation, colony formation, migration and invasion, and osteoclast induction in vitro, and prevented or reduced osteolytic metastases in vivo. 8 15 empty spots were measured. Hybridization signals that failed to exceed the average background value by more than three standard deviations were excluded from analysis. Signal intensities for each spot were calculated by subtracting the background values from the total intensities. Data normalization was performed using positive control RNA spots (tRNA(G), tRNA(L), tRNA(T), tRNA(H) and 5S rRNA) to allow comparisons among chips. The remaining data were averaged among triplicate arrays, and the resulting four data sets, each corresponding to an RNA sample, were considered independent measurements for the purposes of paired, two-sample t test when comparing miRNA profiles in SBC-5 with SBC-3.
Reverse transcriptase (RT) and quantitative real-time PCR were performed in a two-step reaction using Taqman miRNA assays according to the protocol provided by the manufacturer (Applied Biosystems, Foster City, CA). U6 was used as the internal control. The 2 -ΔΔCT method described by Livak and Schmittgen (28) was used to analyze the data.
Stable overexpression of miR-335 or miR-29a in the SBC-5 cell line
A lentiviral expression system was used to establish stable SBC-5 cell lines with high miR-335 or miR-29a expression. Lenti-miR-335 or Lenti-miR-29a miRNA Precursor Expression Construct (System Biosciences, Mountain View, CA) was used to prepare lentivirus with the LentiSuite (System Biosciences, Mountain View, CA) according to the manufacturer's protocol. The pGreenPuro Scramble Hairpin Control Construct (System Biosciences, Mountain View, CA) was used to prepare control lentivirus. Lentiviral infection was performed according to the manufacturer's protocol. Transfected cells were trypsinized, diluted in culture medium and seeded in 96-well plate at one cell/well in average. After 7-day C57BL/6J, Jackson Laboratory, Bar Harbor, ME) were prepared, using the method described by Granholm S.P. et al (29) . The cells were seeded in 24-well plate at 1×10 
RANKL 3′ UTR reporter assay
The potential miR-335 target site predicted by miRanda on RANKL mRNA 3′UTR was amplified from human genomic DNA using the primer pair （ forward: 5′- 
Statistical analyses
Analyses were performed with JMP 8.0 software (SAS, Cary, NC). We used ANOVA to compare multiple groups, followed by pairwise comparisons if significant differences were detected. Tukey-Kramer test was used for comparisons with a control group. Dunnett's test was used to compare all groups. Unpaired t-tests were used to compare data when only two groups were used. Differences were considered statistically significant at P < 0.05 on a two-tailed test. Data were expressed as means ± standard error of the mean (SEM).
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Results

Reduced expression of miR-335 and miR-29a in SBC-5 cells compared to SBC-3 cells
Prior work reports that SBC-5 cells colonize skeletal and non-skeletal tissues, while SBC-3 cells only colonize non-skeletal tissues. This fact indicates that SBC-5 cells may produce specific factors to communicate with osteoclasts and/or osteoblasts to colonize into skeleton. including miR-9, miR-10a, miR-17-92 family, miR-29 family and miR-335, were expressed at lower levels in SBC-5 than in SBC-3 (fold-change >2, p-value <0.001) (Table 1 and Supplementary material, Fig. S1 ). Because microarray data reflects relative differences in miRNA expression patterns of SBC-5 and SBC-3, we determined if candidate miRNAs were also present in human normal lung tissues. Compared to normal lung tissue, miR-335 and miR-29a expression was lower in SBC-5 cells, while no changes were observed for the other miRNAs. Based on these observations, we focused on miR-335 and miR-29a and excluded the other miRNAs (Fig. 1) .
Over-expression of miR-335, but not miR-29a, reduces in vitro carcinogenesis
Using a lentiviral transfection strategy, miR-335 or miR-29a genes were stably transfected into SBC-5 respectively. The lentivirus system enabled external miRNA gene expression from the constitutive CMV promoter and contained copGFP as a reporter. Lentiviral Ctrl (Fig. 4) . Using miRanda software, we identified RANKL, a key cytokine regulating osteoclastogenesis, as a candidate target for miR-335. We found that RANKL expression was higher in cell lysates and culture medium of SBC-5, than that in SBC-3. We confirmed that significantly reduced luciferase activity of the construct containing the target site of RANKL 3′UTR. When the target sequence was mutated, miR-335 failed to reduce luciferase activity (Fig. 5D-E hypermethylation of the miR-335 locus on 7q32.2 appeared to be a common feature, resulting in the designation of miR-335 as a "selective metastasis suppressor and tumor initiation suppressor locus in human breast cancer" (43) . In breast cancer, expression of miR-335 activated the tumor suppressor gene BRCA1 via effects on BRCA1 repressor ID4, resulting in increased apoptosis by down-regulation of ERα and IGF-1R (32). In gastric cancer cell lines, miR-335 targeted Bcl-w and specificity protein 1, both of which have also been linked to metastatic progression (44) . Our data strongly suggests increased miR-335 may mitigate human metastatic SCLC, but clinical research is needed to validate this speculation, and to determine if there are common mechanisms regulated by miRNA across cancer types.
Down-regulation of osteoclast induction and RANKL expression in SBC-
We speculated that miR-335 might target cytokines linked to osteoclast induction and bone turnover. We report two cytokines, IGF-1R and RANKL, both of which have been 
